Fibrosis - A lethal component of systemic sclerosis

Nature Reviews Rheumatology

Volumn 10, Issue 7, 2014, Pages 390-402

  Ho, Yuen Yee ^a   Lagares, David ^b   Tager, Andrew M ^b   Kapoor, Mohit ^c  

^a MCGILL UNIVERSITY   (Canada)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; FOCAL ADHESION KINASE; HEAT SHOCK PROTEIN 90; LYSOPHOSPHATIDIC ACID; LYSYL OXIDASE LIKE 2; NOTCH RECEPTOR; OXIDOREDUCTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN MKL1; PROTEIN ROCK1; PROTEIN ROCK2; PROTEIN TAZ; PROTEIN YAP; RHO KINASE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN;

ADAPTIVE IMMUNITY; AUTOPHAGY; CELL ACTIVATION; CELL DIFFERENTIATION; CHRONIC DISEASE; ENDOTHELIUM; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; INNATE IMMUNITY; MATRIX STIFFNESS; MECHANICS; MECHANOTRANSDUCTION; MYOFIBROBLAST; NONHUMAN; NOTCH SIGNALING PATHWAY; PERICYTE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TH1 TH2 BALANCE; TISSUE INJURY; WNT SIGNALING PATHWAY;

AUTOANTIBODIES; CELL DIFFERENTIATION; ENDOPLASMIC RETICULUM; ENDOTHELIUM; FIBROBLASTS; FIBROSIS; HUMANS; PERICYTES; SCLERODERMA, SYSTEMIC; SKIN; STRESS, MECHANICAL; TRANSCRIPTION FACTORS;

EID: 84903694364     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2014.53     Document Type: Review

References (157)

1. Guillevin, L. et al. Functional impairment of systemic scleroderma patients with digital ulcerations: Results from the DUO Registry. Clin. Exp. Rheumatol. 31, 71Y80 (2013
2. Gelber, A. C. et al. Race and association with disease manifestations and mortality in scleroderma: A 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature. Medicine (Baltimore) 92, 191Y205 (2013
3. Nikpour, M. & Baron, M. Mortality in systemic sclerosis: Lessons learned from population-based and observational cohort studies. Curr. Opin. Rheumatol. 26, 131Y137 (2014
4. Bhattacharyya, S., Wei, J. & Varga, J. Understanding fibrosis in systemic sclerosis: Shifting paradigms, emerging opportunities. Nat. Rev. Rheumatol. 8, 42Y54 (2012
5. Trojanowska, M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat. Rev. Rheumatol. 6, 453Y460 (2010
6. Hachulla, E. & Launay, D. Diagnosis and classification of systemic sclerosis. Clin. Rev. Allergy Immunol. 40, 78Y83 (2011
7. Rudnicka, L. et al. Elevated expression of type VII collagen in the skin of patients with systemic sclerosis. Regulation by transforming growth factor-beta. J. Clin. Invest. 93, 1709Y1715 (1994
8. Makino, K. et al. The downregulation of microRNA let-7a contributes to the excessive expression of type I collagen in systemic and localized scleroderma. J. Immunol. 190, 3905Y3915 (2013
9. Maurer, B. et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 62, 1733Y1743 (2010
10. Honda, N. et al. miR-150 down-regulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin β3. Am. J. Pathol. 182, 206Y216 (2013
11. Chanoki, M. et al. Increased expression of lysyl oxidase in skin with scleroderma. Br. J. Dermatol. 133, 710Y715 (1995
12. Fleming, J. N. et al. Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis. PLoS ONE 4, e6203 (2009
13. Manetti, M. et al. Evidence for progressive reduction and loss of telocytes in the dermal cellular network of systemic sclerosis. J. Cell. Mol. Med. 17, 482Y496 (2013
14. Ceafalan, L., Gherghiceanu, M., Popescu, L. M. & Simionescu, O. Telocytes in human skin - are they involved in skin regeneration? J. Cell. Mol. Med. 16, 1405Y1420 (2012
15. Bani, D., Formigli, L., Gherghiceanu, M. & Faussone-Pellegrini, M. S. Telocytes as supporting cells for myocardial tissue organization in developing and adult heart. J. Cell. Mol. Med. 14, 2531Y2538 (2010
16. Popescu, L. M., Gherghiceanu, M., Suciu, L. C., Manole, C. G. & Hinescu, M. E. Telocytes and putative stem cells in the lungs: Electron microscopy, electron tomography and laser scanning microscopy. Cell Tissue Res. 345, 391Y403 (2011
17. Milano, A. et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 3, e2696 (2008
18. Gardner, H. et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum. 54, 1961Y1973 (2006
19. Guiducci, S., Giacomelli, R. & Cerinic, M. M. Vascular complications of scleroderma. Autoimmun. Rev. 6, 520Y523 (2007
20. Kuwana, M., Okazaki, Y., Yasuoka, H., Kawakami, Y. & Ikeda, Y. Defective vasculogenesis in systemic sclerosis. Lancet 364, 603Y610 (2004
21. Rabquer, B. J. & Koch, A. E. Angiogenesis and vasculopathy in systemic sclerosis: Evolving concepts. Curr. Rheumatol. Rep. 14, 56Y63 (2012
22. Morgan-Rowe, L. et al. Thrombospondin 1 in hypoxia-conditioned media blocks the growth of human microvascular endothelial cells and is increased in systemic sclerosis tissues. Fibrogenesis Tissue Repair 4, 13 (2011
23. Koch, A. E. et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology 61, 239Y246 (1993
24. Gruschwitz, M. S. & Vieth, G. Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage. Arthritis Rheum. 40, 540Y550 (1997
25. Rajkumar, V. S., Sundberg, C., Abraham, D. J., Rubin, K. & Black, C. M. Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum. 42, 930Y941 (1999
26. Rajkumar, V. S. et al. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res. Ther. 7, R1113YR1123 (2005
27. Lin, S. L., Kisseleva, T., Brenner, D. A. & Duffield, J. S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am. J. Pathol. 173, 1617Y1627 (2008
28. Amodio, G. & Gregori, S. Dendritic cells a double-edge sword in autoimmune responses. Front. Immunol. 3, 233 (2012
29. Nace, G., Evankovich, J., Eid, R. & Tsung, A. Dendritic cells and damage-associated molecular patterns: Endogenous danger signals linking innate and adaptive immunity. J. Innate Immun. 4, 6Y15 (2012
30. Lu, T. T. Dendritic cells: Novel players in fibrosis and scleroderma. Curr. Rheumatol. Rep. 14, 30Y38 (2012
31. Granucci, F., Zanoni, I. & Ricciardi-Castagnoli, P. Central role of dendritic cells in the regulation and deregulation of immune responses. Cell. Mol. Life Sci. 65, 1683Y1697 (2008
32. van Bon, L., Cossu, M. & Radstake, T. R. An update on an immune system that goes awry in systemic sclerosis. Curr. Opin. Rheumatol 23, 505Y510 (2011
33. Sugiura, H. et al. Activation of Toll-like receptor 3 augments myofibroblast differentiation. Am. J. Respir. Cell. Mol. Biol. 40, 654Y662 (2009
34. Meneghin, A. et al. TLR9 is expressed in idiopathic interstitial pneumonia and its activation promotes in vitro myofibroblast differentiation. Histochem. Cell Biol. 130, 979Y992 (2008
35. Farina, G. A. et al. Poly(I:C) drives type I IFN- and TGFβ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J. Invest. Dermatol. 130, 2583Y2593 (2010
36. van Lieshout, A. W. et al. Enhanced interleukin-10 production by dendritic cells upon stimulation with Toll-like receptor 4 agonists in systemic sclerosis that is possibly implicated in CCL18 secretion. Scand. J. Rheumatol. 38, 282Y290 (2009
37. Fineschi, S. et al. Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of Toll-like receptor 4. Arthritis Rheum. 58, 3913Y3923 (2008
38. Roumm, A. D. et al. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum. 27, 645Y653 (1984
39. Gustafsson, R., Tötterman, T. H., Klareskog, L. & Hällgren, R. Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis. Ann. Rheum. Dis. 49, 40Y45 (2003
40. Zuber, J. P. & Spertini, F. Immunological basis of systemic sclerosis. Rheumatology (Oxford) 45 (Suppl. 3), iii23Yiii25 (2006
41. Yukawa, S. et al. Involvement of mast cells in systemic sclerosis. Nihon Rinsho Meneki Gakkai Kaishi 33, 81Y86 (2010
42. Duncan, M. R. & Berman, B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J. Invest. Dermatol. 97, 686Y692 (1991
43. Wynn, T. A. Fibrotic disease and the TH1/TH2 paradigm. Nat. Rev. Immunol. 4, 583Y594 (2004
44. Hasegawa, M., Fujimoto, M., Kikuchi, K. & Takehara, K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J. Rheumatol 24, 328Y332 (1997
45. Bhogal, R. K. & Bona, C. A. Regulatory effect of extracellular signal-regulated kinases (ERK) on type I collagen synthesis in human dermal fibroblasts stimulated by IL-4 and IL-13. Int. Rev. Immunol. 27, 472Y496 (2008
46. Jinnin, M., Ihn, H., Yamane, K. & Tamaki, K. Interleukin-13 stimulates the transcription of the human α2(I) collagen gene in human dermal fibroblasts. J. Biol. Chem. 279, 41783Y41791 (2004
47. Yamamoto, T. Autoimmune mechanisms of scleroderma and a role of oxidative stress. Self Nonself 2, 4Y10 (2011
48. Wen, F. Q. et al. Interleukin-4-and interleukin-13-enhanced transforming growth factor-β2 production in cultured human bronchial epithelial cells is attenuated by interferon-gamma. Am. J. Respir. Cell. Mol. Biol. 26, 484Y490 (2002
49. Feghali, C. A., Bost, K. L., Boulware, D. W. & Levy, L. S. Human recombinant interleukin-4 induces proliferation and interleukin-6 production by cultured human skin fibroblasts. Clin. Immunol. Immunopathol. 63, 182Y187 (1992
50. Lee, Y. W., Kuhn, H., Hennig, B., Neish, A. S. & Toborek, M. IL-4-induced oxidative stress upregulates VCAM-1 gene expression in human endothelial cells. J. Mol. Cell Cardiol. 33, 83Y94 (2001
51. Atamas, S. P. et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum. 42, 1168Y1178 (1999
52. Riccieri, V. et al. Interleukin-13 in systemic sclerosis: Relationship to nailfold capillaroscopy abnormalities. Clin. Rheumatol. 22, 102Y106 (2003
53. Aliprantis, A. O. et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc. Natl Acad. Sci. USA 104, 2827Y2830 (2007
54. Fuschiotti, P. Role of IL-13 in systemic sclerosis. Cytokine 56, 544Y549 (2011
55. Fuschiotti, P., Medsger, T. A., Jr & Morel, P. A. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum. 60, 1119Y1128 (2009
56. Rincon, M., Anguita, J., Nakamura, T., Fikrig, E. & Flavell, R. A. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J. Exp. Med. 185, 461Y469 (1997
57. Hsieh, C. S., Heimberger, A. B., Gold, J. S., O'Garra, A. & Murphy, K. M. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an αβ T-cell-receptor transgenic system. Proc. Natl Acad. Sci. USA 89, 6065Y6069 (1992
58. Fielding, C. A. et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40, 40Y50 (2014
59. Hasegawa, M. et al. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J. Rheumatol 25, 308Y313 (1998
60. Gallucci, R. M., Lee, E. G. & Tomasek, J. J. IL-6 modulates alpha-smooth muscle actin expression in dermal fibroblasts from IL-6-deficient mice. J. Invest. Dermatol. 126, 561Y568 (2006
61. Elhai, M. et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: A EUSTAR observational study. Ann. Rheum. Dis. 72, 1217Y1220 (2013
62. Shima, Y. et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 49, 2408Y2412 (2010
63. Md Yusof, M. Y. & Emery, P. Targeting interleukin-6 in rheumatoid arthritis. Drugs 73, 341Y356 (2013
64. Cepeda, E. J. & Reveille, J. D. Autoantibodies in systemic sclerosis and fibrosing syndromes: Clinical indications and relevance. Curr. Opin. Rheumatol. 16, 723Y732 (2004
65. Sato, S., Hamaguchi, Y., Hasegawa, M. & Takehara, K. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology (Oxford) 40, 1135Y1140 (2001
66. Baroni, S. S. et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N. Engl. J. Med. 354, 2667Y2676 (2006
67. Ronda, N. et al. Antifibroblast antibodies from systemic sclerosis patients are internalized by fibroblasts via a caveolin-linked pathway. Arthritis Rheum. 46, 1595Y1601 (2002
68. Tan, F. K. et al. Autoantibodies to fibrillin 1 in systemic sclerosis: Ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. Arthritis Rheum. 43, 2464Y2471 (2000
69. Nishijima, C. et al. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin. Exp. Immunol. 138, 357Y363 (2004
70. Lenna, S. & Trojanowska, M. The role of endoplasmic reticulum stress and the unfolded protein response in fibrosis. Curr. Opin. Rheumatol. 24, 663Y668 (2012
71. Tanjore, H., Lawson, W. E. & Blackwell, T. S. Endoplasmic reticulum stress as a pro-fibrotic stimulus. Biochim. Biophys. Acta 1832, 940Y947 (2013
72. Bertolotti, A., Zhang, Y., Hendershot, L. M., Harding, H. P. & Ron, D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat. Cell Biol. 2, 326Y332 (2000
73. Moore, K. A. & Hollien, J. The unfolded protein response in secretory cell function. Annu. Rev. Genet. 46, 165Y183 (2012
74. Lenna, S. et al. Increased expression of endoplasmic reticulum stress and unfolded protein response genes in peripheral blood mononuclear cells from patients with limited cutaneous systemic sclerosis and pulmonary arterial hypertension. Arthritis Rheum. 65, 1357Y1366 (2013
75. Ding, W. X. & Yin, X. M. Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome. Autophagy 4, 141Y150 (2008
76. Ishida, Y. & Nagata, K. Autophagy eliminates a specific species of misfolded procollagen and plays a protective role in cell survival against ER stress. Autophagy 5, 1217Y1219 (2009
77. Castello-Cros, R. et al. Scleroderma-like properties of skin from caveolin-1-deficient mice: Implications for new treatment strategies in patients with fibrosis and systemic sclerosis. Cell Cycle 10, 2140Y2150 (2011
78. Picard, D. Heat-shock protein 90, a chaperone for folding and regulation. Cell. Mol. Life Sci. 59, 1640Y1648 (2002
79. Wrighton, K. H., Lin, X. & Feng, X. H. Critical regulation of TGFβ signaling by Hsp90. Proc. Natl Acad. Sci. USA 105, 9244Y9249 (2008
80. Tomcik, M. et al. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2012-203095
81. Miyoshi, S., Yamazaki, S., Uchiumi, A. & Katagata, Y. The Hsp90 inhibitor 17-AAG represses calcium-induced cytokeratin 1 and 10 expression in HaCaT keratinocytes. FEBS Open Bio. 2, 47Y50 (2012
82. Noh, H. et al. Heat shock protein 90 inhibitor attenuates renal fibrosis through degradation of transforming growth factor-beta type II receptor. Lab. Invest. 92, 1583Y1596 (2012
83. Santiago, B., Galindo, M., Rivero, M. & Pablos, J. L. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum. 44, 1667Y1676 (2001
84. Hinz, B., Dugina, V., Ballestrem, C., Wehrle-Haller, B. & Chaponnier, C. Alpha-smooth muscle actin is crucial for focal adhesion maturation in myofibroblasts. Mol. Biol. Cell 14, 2508Y2519 (2003
85. Jelaska, A., Arakawa, M., Broketa, G. & Korn, J. H. Heterogeneity of collagen synthesis in normal and systemic sclerosis skin fibroblasts. Increased proportion of high collagen-producing cells in systemic sclerosis fibroblasts. Arthritis Rheum. 39, 1338Y1346 (1996
86. Moulin, V. et al. Normal skin wound and hypertrophic scar myofibroblasts have differential responses to apoptotic inductors. J. Cell Physiol. 198, 350Y358 (2004
87. Hoyles, R. K. et al. An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor beta receptor. Am. J. Respir. Crit. Care Med. 183, 249Y261 (2011
88. Vannella, K. M. et al. Cysteinyl leukotrienes are autocrine and paracrine regulators of fibrocyte function. J. Immunol. 179, 7883Y7890 (2007
89. Mehrad, B., Burdick, M. D. & Strieter, R. M. Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int. J. Biochem. Cell Biol. 41, 1708Y1718 (2009
90. Distler, J. H. et al. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum. 56, 4203Y4215 (2007
91. Humphreys, B. D. et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176, 85Y97 (2010
92. Taura, K. et al. Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology 51, 1027Y1036 (2010
93. Rock, J. R. et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc. Natl Acad. Sci. USA 108, E1475YE1483 (2011
94. Zeisberg, E. M. et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 13, 952Y961 (2007
95. Biernacka, A., Dobaczewski, M. & Frangogiannis, N. G. TGF-β signaling in fibrosis. Growth Factors 29, 196Y202 (2011
96. Kitani, A. et al. Transforming growth factor (TGF)-β1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-β1-mediated fibrosis. J. Exp. Med. 198, 1179Y1188 (2003
97. Radstake, T. R. et al. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFβ expression. PLoS ONE 4, e5981 (2009
98. Denton, C. P. et al. Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 56, 323Y333 (2007
99. Tager, A. M. et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat. Med. 14, 45Y54 (2008
100. Pradere, J. P. et al. LPA1 receptor activation promotes renal interstitial fibrosis. J. Am. Soc. Nephrol. 18, 3110Y3118 (2007
101. Sakai, N. et al. LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation. FASEB J. 27, 1830Y1846 (2013
102. Watanabe, N. et al. Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity. Life Sci. 81, 1009Y1015 (2007
103. Watanabe, N. et al. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J. Clin. Gastroenterol. 41, 616Y623 (2007
104. Nikitopoulou, I. et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J. Exp. Med. 209, 925Y933 (2012
105. Bourgoin, S. G. & Zhao, C. Autotaxin and lysophospholipids in rheumatoid arthritis. Curr. Opin. Investig. Drugs 11, 515Y526 (2010
106. Pattanaik, D. & Postlethwaite, A. E. A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis. Discov. Med. 10, 161Y167 (2010
107. Castelino, F. V. Lipids and eicosanoids in fibrosis: Emerging targets for therapy. Curr. Opin. Rheumatol. 24, 649Y655 (2012
108. Sevastou, I., Kaffe, E., Mouratis, M. A. & Aidinis, V. Lysoglycerophospholipids in chronic inflammatory disorders: The PLA(2)/LPC and ATX/LPA axes. Biochim. Biophys. Acta 1831, 42Y60 (2013
109. Mutoh, T., Rivera, R. & Chun, J. Insights into the pharmacological relevance of lysophospholipid receptors. Br. J. Pharmacol. 165, 829Y844 (2012
110. Castelino, F. V. et al. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum. 63, 1405Y1415 (2011
111. Mazereeuw-Hautier, J. et al. Production of lysophosphatidic acid in blister fluid: Involvement of a lysophospholipase D activity. J. Invest. Dermatol. 125, 421Y427 (2005
112. Tokumura, A. et al. Elevated serum levels of arachidonoyl- lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int. J. Med. Sci. 6, 168Y176 (2009
113. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01651143 (2014
114. Memon, R. A. et al. Up-regulation of peroxisome proliferator-activated receptors (PPAR-α) and PPAR-γ messenger ribonucleic acid expression in the liver in murine obesity: Troglitazone induces expression of PPAR-γ-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 141, 4021Y4031 (2000
115. Ghosh, A. K. et al. Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J. 23, 2968Y2977 (2009
116. Wu, M. et al. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-γ. Am. J. Pathol. 174, 519Y533 (2009
117. Wei, J. et al. A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-gamma-independent suppression of fibrotic responses. Ann. Rheum. Dis. 73, 446Y454 (2013
118. Patel, L. et al. Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN. Curr. Biol. 11, 764Y768 (2001
119. Wei, J. et al. PPARγ downregulation by TGFβ in fibroblast and impaired expression and function in systemic sclerosis: A novel mechanism for progressive fibrogenesis. PLoS ONE 5, e13778 (2010
120. Kapoor, M. et al. Loss of peroxisome proliferator-activated receptor γ in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum. 60, 2822Y2829 (2009
121. Chen, Y. et al. Inhibition of Notch signaling by a γ-secretase inhibitor attenuates hepatic fibrosis in rats. PLoS ONE 7, e46512 (2012
122. Dees, C. et al. Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann. Rheum. Dis. 70, 1304Y1310 (2011
123. Dees, C. et al. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum. 63, 1396Y1404 (2011
124. Wei, J. et al. Wnt/β-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum. 64, 2734Y2745 (2012
125. Wei, J et al. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: A novel mouse model for scleroderma? Arthritis Rheum. 63, 1707Y1717 (2011
126. Wang, P. S. et al. Thiazolidinediones downregulate Wnt/β-catenin signaling via multiple mechanisms in breast cancer cells. J. Surg. Res. 153, 210Y216 (2009
127. Shalhoub, V. et al. Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols. Calcif. Tissue Int. 79, 431Y442 (2006
128. Thorne, C. A. et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat. Chem. Biol. 6, 829Y836 (2010
129. Li, J. et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39, 754Y766 (2006
130. Reich, A., Meurer, M., Eckes, B., Friedrichs, J. & Muller, D. J. Surface morphology and mechanical properties of fibroblasts from scleroderma patients. J. Cell. Mol. Med. 13, 1644Y1652 (2009
131. Tschumperlin, D. J., Liu, F. & Tager, A. M. Biomechanical regulation of mesenchymal cell function. Curr. Opin. Rheumatol. 25, 92Y100 (2013
132. Liu, F. et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J. Cell Biol. 190, 693Y706 (2010
133. Barry-Hamilton, V. et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat. Med. 16, 1009Y1017 (2010
134. Kagan, H. M. & Li, W. Lysyl oxidase: Properties, specificity, and biological roles inside and outside of the cell. J. Cell. Biochem. 88, 660Y672 (2003
135. Barker, H. E., Cox, T. R. & Erler, J. T. The rationale for targeting the LOX family in cancer. Nat. Rev. Cancer 12, 540Y552 (2012
136. Meyringer, R. et al. Analysis of gene expression patterns in systemic sclerosis fibroblasts using RNA arbitrarily primed-polymerase chain reaction for differential display. J. Rheumatol. 34, 747Y753 (2007
137. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01362231?term=NCT01362231&rank=1 (2013
138. Geiger, B., Bershadsky, A., Pankov, R. & Yamada, K. M. Transmembrane crosstalk between the extracellular matrix - cytoskeleton crosstalk. Nat. Rev. Mol. Cell Biol. 2, 793Y805 (2001
139. Shi-wen, X. et al. Focal adhesion kinase and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibroblasts. Rheumatology (Oxford) 51, 2146Y2154 (2012
140. Wong, V. W. et al. Focal adhesion kinase links mechanical force to skin fibrosis via inflammatory signaling. Nat. Med. 18, 148Y152 (2012
141. Schultze, A. & Fiedler, W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin. Investig. Drugs 19, 777Y788 (2010
142. Lagares, D. et al. Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation. Arthritis Rheum. 64, 1653Y1664 (2012
143. Akhmetshina, A. et al. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum. 58, 2553Y2564 (2008
144. Huang, X. et al. Relaxin regulates myofibroblast contractility and protects against lung fibrosis. Am. J. Pathol. 179, 2751Y2765 (2011
145. Jiang, C. et al. Fasudil, a rho-kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice. Int. J. Mol. Sci. 13, 8293Y8307 (2012
146. Washida, N. et al. Rho-kinase inhibition ameliorates peritoneal fibrosis and angiogenesis in a rat model of peritoneal sclerosis. Nephrol. Dial. Transplant. 26, 2770Y2779 (2011
147. Ishimaru, K. et al. Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats. J. Cardiovasc. Pharmacol. 50, 187Y194 (2007
148. Zhou, Y. et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J. Clin. Investig. 123, 1096Y1108 (2013
149. Velasquez, L. S. et al. Activation of MRTF-A-dependent gene expression with a small molecule promotes myofibroblast differentiation and wound healing. Proc. Natl Acad. Sci. USA 110, 16850Y16855 (2013
150. Sakai, N. et al. LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation. FASEB J. 27, 1830Y1846 (2013
151. Small, E. M. et al. Myocardin-related transcription factor-a controls myofibroblast activation and fibrosis in response to myocardial infarction. Circulation Res. 107, 294Y304 (2010
152. Luchsinger, L. L., Patenaude, C. A., Smith, B. D. & Layne, M. D. Myocardin-related transcription factor-A complexes activate type I collagen expression in lung fibroblasts. J. Biol. Chem. 286, 44116Y44125 (2011
153. Dupont, S. et al. Role of YAP/TAZ in mechanotransduction. Nature 474, 179Y183 (2011
154. Yu, F. X. et al. Regulation of the Hippo-YAP pathway by G.-protein-coupled receptor signaling. Cell 150, 780Y791 (2012
155. Varelas, X. et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat. Cell Biol. 10, 837Y848 (2008
156. Liu-Chittenden, Y. et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26, 1300Y1305 (2012
157. Denton, C. P. & Ong, V. H. Targeted therapies for systemic sclerosis. Nat. Rev. Rheumatol. 9, 451Y464 (2013.